These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36851760)

  • 41. Performance of Celera RUO integrase resistance assay across multiple HIV-1 subtypes.
    Wallis CL; Viana RV; Saravanan S; Silva de Jesus C; Zeh C; Halvas EK; Mellors JW
    J Virol Methods; 2017 Mar; 241():41-45. PubMed ID: 27993614
    [TBL] [Abstract][Full Text] [Related]  

  • 42. No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartments.
    Abdi B; Chebbi M; Wirden M; Teyssou E; Sayon S; Palich R; Seang S; Valantin MA; Simon A; Tubiana R; Katlama C; Calvez V; Marcelin AG; Soulie C
    J Antimicrob Chemother; 2021 May; 76(6):1553-1557. PubMed ID: 33693680
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa.
    Inzaule SC; Hamers RL; Noguera-Julian M; Casadellà M; Parera M; Rinke de Wit TF; Paredes R
    J Antimicrob Chemother; 2018 May; 73(5):1167-1172. PubMed ID: 29462322
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Natural polymorphisms of integrase among HIV type 1-infected South African patients.
    Fish MQ; Hewer R; Wallis CL; Venter WD; Stevens WS; Papathanasopoulos MA
    AIDS Res Hum Retroviruses; 2010 Apr; 26(4):489-93. PubMed ID: 20377427
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.
    Roquebert B; Damond F; Collin G; Matheron S; Peytavin G; Bénard A; Campa P; Chêne G; Brun-Vézinet F; Descamps D;
    J Antimicrob Chemother; 2008 Nov; 62(5):914-20. PubMed ID: 18718922
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Circulating HIV-1 Integrase Genotypes in Tanzania: Implication on the Introduction of Integrase Inhibitors-Based Antiretroviral Therapy Regimen.
    Masoud S; Kamori D; Barabona G; Mahiti M; Sunguya B; Lyamuya E; Ueno T
    AIDS Res Hum Retroviruses; 2020 Jun; 36(6):539-543. PubMed ID: 32126792
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lack of integrase inhibitors associated resistance mutations among HIV-1C isolates.
    Mulu A; Maier M; Liebert UG
    J Transl Med; 2015 Dec; 13():377. PubMed ID: 26626277
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pre-Treatment Integrase Inhibitor Resistance and Natural Polymorphisms among HIV-1 Subtype C Infected Patients in Ethiopia.
    Arimide DA; Szojka ZI; Zealiyas K; Gebreegziabxier A; Adugna F; Sasinovich S; Björkman P; Medstrand P
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458459
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pre-treatment integrase inhibitor resistance is uncommon in antiretroviral therapy-naive individuals with HIV-1 subtype A1 and D infections in Uganda.
    McCluskey SM; Kamelian K; Musinguzi N; Kigozi S; Boum Y; Bwana MB; Muzoora C; Brumme ZL; Carrington M; Carlson J; Foley B; Hunt PW; Martin JN; Bangsberg DR; Harrigan PR; Siedner MJ; Haberer JE; Lee GQ
    AIDS; 2021 Jun; 35(7):1083-1089. PubMed ID: 33635845
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-Naive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1.
    Sayan M; Yildirim FS; Akhan S; Karaoglan I; Akalin H
    Curr HIV Res; 2022 Aug; 20(2):184-192. PubMed ID: 35240975
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quantitative prediction of integrase inhibitor resistance from genotype through consensus linear regression modeling.
    Van der Borght K; Verheyen A; Feyaerts M; Van Wesenbeeck L; Verlinden Y; Van Craenenbroeck E; van Vlijmen H
    Virol J; 2013 Jan; 10():8. PubMed ID: 23282253
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Drug resistance mutations of HIV type 1 non-B viruses to integrase inhibitors in treatment-naive patients from sub-saharan countries and discordant interpretations.
    Monleau M; Aghokeng AF; Nkano BA; Chaix ML; Peeters M;
    AIDS Res Hum Retroviruses; 2012 Sep; 28(9):1157-60. PubMed ID: 22236055
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Transmitted drug resistance mutations and trends of HIV-1 subtypes in treatment-naïve patients: A single-centre experience.
    Mazzuti L; Melengu T; Falasca F; Calabretto M; Cella E; Ciccozzi M; Mezzaroma I; Iaiani G; Spaziante M; d'Ettorre G; Fimiani C; Vullo V; Antonelli G; Turriziani O
    J Glob Antimicrob Resist; 2020 Mar; 20():298-303. PubMed ID: 31518723
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings.
    Semengue ENJ; Armenia D; Inzaule S; Santoro MM; Dambaya B; Takou D; Teto G; Nka AD; Yagai B; Fabeni L; Chenwi C; Angong Beloumou G; Djupsa Ndjeyep SC; Colizzi V; Perno CF; Ceccherini-Silberstein F; Fokam J
    J Antimicrob Chemother; 2021 Apr; 76(5):1277-1285. PubMed ID: 33501504
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations.
    Winters MA; Lloyd RM; Shafer RW; Kozal MJ; Miller MD; Holodniy M
    PLoS One; 2012; 7(7):e40514. PubMed ID: 22815755
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification and characterization of CRF02_AG, CRF06_cpx, and CRF09_cpx recombinant subtypes in Mali, West Africa.
    Imamichi H; Koita O; Dabitao D; Dao S; Ibrah M; Sogoba D; Dewar RL; Berg SC; Jiang MK; Parta M; Washington JA; Polis MA; Lane HC; Tounkara A
    AIDS Res Hum Retroviruses; 2009 Jan; 25(1):45-55. PubMed ID: 19182920
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Natural polymorphisms of HIV-1 subtype-C integrase coding region in a large group of ARV-naïve infected individuals.
    Dimonte S; Babakir-Mina M; Aquaro S; Perno CF
    Infection; 2013 Dec; 41(6):1097-102. PubMed ID: 23620062
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevalence of Integrase Strand Transfer Inhibitors Resistance Mutations in Integrase Strand Transfer Inhibitors-Naive and -Experienced HIV-1 Infected Patients: A Single Center Experience.
    De Francesco MA; Izzo I; Properzi M; Gargiulo F; Caccuri F; Quiros-Roldan E; Castelli F; Caruso A; Focà E
    AIDS Res Hum Retroviruses; 2018 Jul; 34(7):570-574. PubMed ID: 29631420
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Detection of drug resistance-associated mutations in human immunodeficiency virus type 1 integrase derived from drug-naive individuals in Surabaya, Indonesia.
    Kotaki T; Khairunisa SQ; Sukartiningrum SD; Witaningrum AM; Rusli M; Diansyah MN; Arfijanto MV; Rahayu RP; Nasronudin ; Kameoka M
    AIDS Res Hum Retroviruses; 2014 May; 30(5):489-92. PubMed ID: 24328535
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.
    Malet I; Wirden M; Fourati S; Armenia D; Masquelier B; Fabeni L; Sayon S; Katlama C; Perno CF; Calvez V; Marcelin AG; Ceccherini-Silberstein F
    J Antimicrob Chemother; 2011 Jul; 66(7):1481-3. PubMed ID: 21474479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.